| 1.2701 -0.28 (-18.06%) | 11-19 15:14 | |||||||||||||
|
|
| Short term | ||||
| Mid term | ||||
| Targets | 6-month : | 1.96 | 1-year : | 2.29 |
| Resists | First : | 1.67 | Second : | 1.96 |
| Pivot price | 1.36 |
|||
| Supports | First : | 1.21 | Second : | 0.92 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 1.28 |
| MA(100) : | 1.77 |
MA(250) : | 1.78 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 85.3 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 2.99 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMMB ] has closed above bottom band by 46.7%. Bollinger Bands are 32.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.56 - 1.57 | 1.57 - 1.57 |
| Low: | 1.43 - 1.44 | 1.44 - 1.45 |
| Close: | 1.53 - 1.55 | 1.55 - 1.56 |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Tue, 17 Nov 2026
Live Chemomab Therapeutics Ltd. (CMMB) Technical Analysis - Traders Union
Wed, 11 Nov 2026
Chemomab Therapeutics Ltd. Stock Price Prediction: Today, Tomorrow, Next Week (CMMB) - Traders Union
Mon, 02 Nov 2026
Chemomab Therapeutics Ltd. SEC Filing (Nov 2, 2026) - Stock Titan
Wed, 30 Sep 2026
Ownership split stays unchanged as Chemomab (CMMB) amends its Scipher merger terms. - Stock Titan
Thu, 09 Jul 2026
Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow - Seeking Alpha
Wed, 27 May 2026
CMMB - Chemomab Therapeutics Ltd ADR Stock Price and Quote - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 22.5 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 82 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.3 % |
| Return on Equity (ttm) | -82.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |